205 related articles for article (PubMed ID: 1828134)
1. Randomized study of vancomycin versus teicoplanin for the treatment of gram-positive bacterial infections in immunocompromised hosts.
Van der Auwera P; Aoun M; Meunier F
Antimicrob Agents Chemother; 1991 Mar; 35(3):451-7. PubMed ID: 1828134
[TBL] [Abstract][Full Text] [Related]
2. Failure of treatment with teicoplanin at 6 milligrams/kilogram/day in patients with Staphylococcus aureus intravascular infection. The Infectious Diseases Consortium of Oregon.
Gilbert DN; Wood CA; Kimbrough RC
Antimicrob Agents Chemother; 1991 Jan; 35(1):79-87. PubMed ID: 1826594
[TBL] [Abstract][Full Text] [Related]
3. Teicoplanin compared with vancomycin in methicillin-resistant Staphylococcus aureus infections: preliminary results.
Van Laethem Y; Hermans P; De Wit S; Goosens H; Clumeck N
J Antimicrob Chemother; 1988 Jan; 21 Suppl A():81-7. PubMed ID: 2965135
[TBL] [Abstract][Full Text] [Related]
4. Treatment of bone, joint, and vascular-access-associated gram-positive bacterial infections with teicoplanin.
Greenberg RN
Antimicrob Agents Chemother; 1990 Dec; 34(12):2392-7. PubMed ID: 2150908
[TBL] [Abstract][Full Text] [Related]
5. Teicoplanin administration in patients experiencing reactions to vancomycin.
Smith SR; Cheesbrough JS; Makris M; Davies JM
J Antimicrob Chemother; 1989 May; 23(5):810-2. PubMed ID: 2527221
[No Abstract] [Full Text] [Related]
6. Clinical evaluation of teicoplanin for therapy of severe infections caused by gram-positive bacteria.
Glupczynski Y; Lagast H; Van der Auwera P; Thys JP; Crokaert F; Yourassowsky E; Meunier-Carpentier F; Klastersky J; Kains JP; Serruys-Schoutens E
Antimicrob Agents Chemother; 1986 Jan; 29(1):52-7. PubMed ID: 2942100
[TBL] [Abstract][Full Text] [Related]
7. Teicoplanin in the treatment of infection caused by gram-positive organisms.
Williams AH; Grüneberg RN; Webster A; Ridgway GL
J Hosp Infect; 1986 Mar; 7 Suppl A():101-3. PubMed ID: 2871091
[TBL] [Abstract][Full Text] [Related]
8. Randomized prospective study comparing vancomycin with teicoplanin in the treatment of infections associated with Hickman catheters.
Smith SR; Cheesbrough J; Spearing R; Davies JM
Antimicrob Agents Chemother; 1989 Aug; 33(8):1193-7. PubMed ID: 2529814
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of novel glycopeptides versus vancomycin for the treatment of gram-positive bacterial infections including methicillin resistant Staphylococcus aureus: A systematic review and meta-analysis.
Jame W; Basgut B; Abdi A
PLoS One; 2021; 16(11):e0260539. PubMed ID: 34843561
[TBL] [Abstract][Full Text] [Related]
10. Effects of teicoplanin and those of vancomycin in initial empirical antibiotic regimen for febrile, neutropenic patients with hematologic malignancies. Gimema Infection Program.
Menichetti F; Martino P; Bucaneve G; Gentile G; D'Antonio D; Liso V; Ricci P; Nosari AM; Buelli M; Carotenuto M
Antimicrob Agents Chemother; 1994 Sep; 38(9):2041-6. PubMed ID: 7811016
[TBL] [Abstract][Full Text] [Related]
11. Glycopeptide bone penetration in patients with septic pseudoarthrosis of the tibia.
Garazzino S; Aprato A; Baietto L; D'Avolio A; Maiello A; De Rosa FG; Aloj D; Siccardi M; Biasibetti A; Massè A; Di Perri G
Clin Pharmacokinet; 2008; 47(12):793-805. PubMed ID: 19026035
[TBL] [Abstract][Full Text] [Related]
12. Comparison of efficacy and safety of teicoplanin and vancomycin in children with antineoplastic therapy-associated febrile neutropenia and gram-positive bacteremia.
Sidi V; Roilides E; Bibashi E; Gompakis N; Tsakiri A; Koliouskas D
J Chemother; 2000 Aug; 12(4):326-31. PubMed ID: 10949982
[TBL] [Abstract][Full Text] [Related]
13. Teicoplanin in the treatment of skin and soft tissue infections: results of a multicentre study.
Lang E; Földes M; Marghescu S
Infection; 1991; 19(3):190-4. PubMed ID: 1832418
[TBL] [Abstract][Full Text] [Related]
14. A multicentre open clinical trial of teicoplanin in infections caused by gram-positive bacteria.
Lewis P; Garaud JJ; Parenti F
J Antimicrob Chemother; 1988 Jan; 21 Suppl A():61-7. PubMed ID: 2965133
[TBL] [Abstract][Full Text] [Related]
15. Treatment of infections by staphylococci and other gram-positive bacteria with teicoplanin: an open study.
Pauluzzi S; Del Favero A; Menichetti F; Baratta E; Moretti VM; Di Filippo P; Pasticci MB; Guerciolini R; Patoia L; Frongillo RF
J Antimicrob Chemother; 1987 Sep; 20(3):431-8. PubMed ID: 2960643
[TBL] [Abstract][Full Text] [Related]
16. Bactericidal activity and killing rate of serum in volunteers receiving vancomycin or teicoplanin with and without amikacin given intravenously.
Van der Auwera P; Klastersky J
J Antimicrob Chemother; 1987 May; 19(5):623-35. PubMed ID: 2956228
[TBL] [Abstract][Full Text] [Related]
17. [The comparative costs of vancomycin treatment versus teicoplanin in osteoarticular infection caused by methicillin-resistant staphylococci].
Pham Dang C; Gouin F; Touchais S; Richard C; Potel G
Pathol Biol (Paris); 2001 Sep; 49(7):587-96. PubMed ID: 11642024
[TBL] [Abstract][Full Text] [Related]
18. Comparative efficacy and safety of vancomycin versus teicoplanin: systematic review and meta-analysis.
Svetitsky S; Leibovici L; Paul M
Antimicrob Agents Chemother; 2009 Oct; 53(10):4069-79. PubMed ID: 19596875
[TBL] [Abstract][Full Text] [Related]
19. Teicoplanin versus vancomycin in the empirical treatment of febrile neutropenic patients.
Chow AW; Jewesson PJ; Kureishi A; Phillips GL
Eur J Haematol Suppl; 1993; 54():18-24. PubMed ID: 8365461
[TBL] [Abstract][Full Text] [Related]
20. Clinical evaluation of efficacy, pharmacokinetics, and safety of teicoplanin for serious gram-positive infections.
Bibler MR; Frame PT; Hagler DN; Bode RB; Staneck JL; Thamlikitkul V; Harris JE; Haregewoin A; Bullock WE
Antimicrob Agents Chemother; 1987 Feb; 31(2):207-12. PubMed ID: 2952062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
